INTRODUCTION
Liver cancer is the second leading cause of cancer death in men and the sixth leading cause of cancer death in women worldwide. An estimated 748,300 new liver cancer cases and 695,900 liver cancer deaths occurred in 2008. 1 The poor prognosis of this disease is partially due to the lack of an effective means of early diagnosis. As a result, only 30% to 40% of patients with hepatocellular carcinoma (HCC) are candidates for potentially curative treatments at the time of diagnosis.
2 Discovery of an effective and reliable tool for early diagnosis of HCC would play a pivotal role in improving the prognosis of patients with HCC.
MicroRNA was initially identified in 1993 and has drawn significant attention in cancer research after it was linked to oncogenesis and tumor metastasis. [3] [4] [5] [6] Many studies have demonstrated that microRNA expression profiles in HCC and nontumor tissue are significantly different. [7] [8] [9] [10] [11] [12] [13] Additional studies showed the existence of a large amount of stable microRNAs in human serum/plasma, which laid the foundation for studying the role of serum/ plasma microRNAs in the diagnosis and prognosis of HCC. 14, 15 In fact, differential expression of several serum microRNAs, including miR-16, miR-122, miR-21, miR-223, miR-25, miR-375, and let-7f in patients with HCC, patients with hepatitis B, and healthy individuals were reported recently. 9, 16, 17 
JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T
However, those studies were limited by one or more of the following factors: limited number of screened microRNAs, small sample size, failure to differentiate HCC from hepatitis B, and lack of independent validation.
Our study investigated plasma microRNA expression profiles (723 microRNAs) with independent validation in a large cohort of 934 participants, with the intention to identify a panel of microRNAs for the diagnosis of hepatitis B virus (HBV) -related HCC. The cohort included healthy individuals and patients with chronic hepatitis B (CHB), cirrhosis and HBV-related HCC.
PATIENTS AND METHODS

Study Design and Patients
Most HBV-related HCC cases involve two disease processes: the HCC and the disturbed liver function either from hepatitis or cirrhosis. It has been reported that large numbers of microRNAs are released to peripheral blood when liver cell damage occurs. 18 Identifying differential circulating microRNAs by contrasting HCC patients with controls as a whole group, which comprises healthy individuals, as well as the patients with hepatitis B and/or cirrhosis, might run the risk of under-representing the aberrant microRNAs from the healthy or cirrhosis groups. This potential risk could be due to the overwhelming numbers of circulating microRNAs released by the damaged liver cells in patients with hepatitis B. Therefore, the strategy of identifying differential microRNAs for HCC in this study was to choose candidate microRNAs on the basis of pairwise comparison of HCC versus healthy, HCC versus CHB, and HCC versus cirrhosis, respectively.
The 934 blood samples that met the eligibility criteria (Data Supplement  Table 1 ), were collected from Zhongshan Hospital and Shanghai Public Health Clinical Center between August 2008 and June 2010. Those samples were allocated to three phases in chronological order (Fig 1). 1. Discovery phase. One hundred thirty-seven samples, each with 723 microRNAs, were screened with a microarray platform (patient characteristics are presented in Data Supplement Table 2 ). A Mann-Whitney test was performed to discover differentially expressed microRNAs in the three pairwise comparisons: HCC versus healthy, CHB, and cirrhosis, respectively. From the differentially expressed microRNAs (Data Supplement Tables 3A-3C) , seven detectable microRNAs with P value Ͻ .01 and fold expression change Ն 2 were identified between the HCC and healthy groups, seven detectable microRNAs with P value Ͻ 10 Ϫ9 and fold expression change Ն 2 were identified between the HCC and CHB groups, and two detectable microRNAs with P value Ͻ 10 Ϫ9 and fold expression change Ն 2 were identified between the HCC and cirrhosis groups. There was one pair of duplicate microRNAs in the HCC versus healthy and HCC versus CHB comparisons (Data Supplement Table 3D ). Finally, 15 candidate microRNAs discovered via microarrays were selected for further testing by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR).
2. Training phase. The 15 microRNAs discovered via microarray were first tested with qRT-PCR in an independent cohort of plasma samples from 102 participants (Data Supplement Table 4 ). Seven microRNAs that were differentially expressed between the HCC and control groups (healthy, CHB, and cirrhosis) were further tested in an additional 305 participants. These 407 participants were used as the training set to construct the diagnostic microRNA panel based on the logistic regression model for the differentiation between the HCC group and the control group.
3. Validation phase. The parameters of the logistic model from the training phase were applied to an independent cohort of 390 samples for validating the diagnostic performance of the selected microRNA panel.
In each study phase, blood samples were obtained from four categories of participants including healthy individuals and patients with CHB, cirrhosis, and HCC. The investigational protocol was approved by local institutional review boards, and informed consents were obtained from all study participants. 
Microarray and qRT-PCR
First, we used human microRNA microarrays 2.0 from Agilent Technologies (Santa Clara, CA) to identify candidate microRNAs for diagnosing HCC in 137 plasma samples (see Data Supplement for details of microarray hybridizations).
For testing of candidate microRNAs acquired on microarrays, qRT-PCR was performed using Taqman microRNA assays (Applied Biosystems, Foster City, CA). The assays were first performed on 102 samples for 15 candidates (miR-101, miR-122, miR-122*, miR-181d, miR-192, miR-194, miR-19a, miR-19b, miR-21, miR-223, miR-23b, miR-26a, miR-27a, miR-29c, and miR-801) that met the defined criteria (Data Supplement Fig 1) . The expression level of miR-1228 was used as a stable endogenous control for normalization. All assays were carried out in triplicate. A microRNA that showed cycle threshold values above 35 in Ͼ 20% of the 102 samples were excluded from additional statistical analysis.
The assays were further applied on 695 samples for seven candidates (miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801) that were statistically differentially expressed in HCC compared with control (healthy, CHB and cirrhosis).
Statistical Analysis
For microarray analysis, the Mann-Whitney unpaired test was used for the three pairwise comparisons (HCC v healthy, HCC v CHB, and HCC v cirrhosis). 19 For the data obtained by qRT-PCR, the Mann-Whitney unpaired test was used for the comparison between HCC and control. A stepwise logistic regression model was used to select diagnostic microRNA markers based on the training dataset. 20 The predicted probability of being diagnosed with HCC was used as a surrogate marker to construct receiver operating characteristic (ROC) curve. Area under the ROC curve (AUC) was used as an accuracy index for evaluating the diagnostic performance of the selected microRNA panel.
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MedCalc (version 10.4.7.0; MedCalc, Mariakerke, Belgium) software was used to perform the ROC and regression analysis. All P values were two sided.
RESULTS
Patient Characteristics
The characteristics of the study participants were presented in Table 1 . There was no significant difference in the distribution of age and sex between the training and validation data sets for the four groups (healthy, CHB, cirrhosis, and HCC). For participants in the healthy and CHB groups, distribution of serum ALT was similar between the training and validation data sets. In the cirrhosis group, there were more patients with deranged liver function (ALT Ͼ 40) in the validation data set than in the training data set (61% v 35%, respectively; P ϭ .01). In the HCC group, there were fewer patients with deranged liver function in the validation data set than in the training data set (24% v 34%, respectively; P ϭ .04). Serum alpha feto-protein (AFP) level was well balanced between the training and validation data sets. In the HCC groups, all of the tumor characteristics except tumor size were similar between the two data sets. There were significantly fewer patients with tumors Ͼ 3 cm in the validation data set than in the training data set (54% v 67%, respectively; P ϭ .01).
MicroRNA Screening and Testing
A microarray containing probes for 723 human microRNAs was initially used to screen the significant differential expression levels of microRNAs between the HCC and control groups (Data Supplement  Table 3 ). Appendix Figure A1 (online only) illustrates the hierarchical clustering of the differentially expressed microRNAs in the pairwise comparison of the HCC and healthy groups, HCC and CHB groups, and HCC and cirrhosis groups, respectively. There were six microRNAs, including miR-122, miR-192, miR-194, miR-21, miR-23b, and miR-801, with significantly higher expression levels in the HCC group than in the healthy group (fold change ϭ 2.0-6.7; P Ͻ .01; Data Supplement Table 3D ). In contrast, miR-223 had a significantly lower expression level in the HCC group than in the healthy group (fold change ϭ 0.5; P Ͻ .01). When compared with patients with CHB, patients with HCC had significantly lower expression levels of miR-101, miR-122*, miR-19a, miR-19b, miR-223, miR27a, and miR-29c (fold change ϭ 0.007-0.2; P Ͻ 10 Ϫ9 ). When compared with patients with cirrhosis, those with HCC had significantly lower expression levels of miR-181d and miR-26a (fold change ϭ 0.1; P Ͻ 10 Ϫ9 ). In summary, 15 differentially expressed microRNAs were identified as candidates for further testing via qRT-PCR.
Differential Expression Profile of Seven Selected MicroRNAs
The 15 candidate microRNAs were first tested using an independent cohort of 102 plasma samples with qRT-PCR, and 12 of the 15 microRNAs passed the quality control. Seven of the 12 microRNAs had significantly different expression levels between the HCC and control groups (Data Supplement Table 4 ). The expression profile of those seven individual microRNAs was further evaluated with qRT-PCR on 305 additional plasma samples. The combined 407 plasma samples were used as the training data set for the construction of the microRNA panel for use in the diagnosis of HCC.
MicroRNA Expression Profile for HCC Versus Control in the Training Data Set
Low expression levels of miR-122, miR-223, miR-26a, and miR27a were observed in patients with HCC compared with those in the control group (fold changes ϭ 0.7, 0.3, 0.2, and 0.3 for miR-122, miR-223, miR-26a, and miR-27a, respectively; Table 2 ). The diagnostic accuracy of these four microRNAs, measured by AUC, was 0.553, 0.643, 0.665, and 0.638, respectively. High expression levels of miR-192, miR-21, and miR-801 were observed in patients with HCC compared with those in the control group (fold change ϭ 1.4, 1.9, and 2.0 for miR-192, miR-21, and miR-801, respectively, Table 2 ). The corresponding AUCs were 0.569, 0.626, and 0.629, respectively. The multivariate P values for all of seven microRNAs were Ͻ .05 (Table 2) .
Establishing the Predictive MicroRNA Panel
A stepwise logistic regression model to estimate the risk of being diagnosed with HCC was applied on the training data set (407 plasma samples). All of the seven microRNAs turned out to be significant predictors ( Table 2 ). The predicted probability of being diagnosed with HCC from the logit model based on the seven microRNA panel, logit(p ϭ HCC) ϭ Ϫ1.424 Ϫ 0.292 ϫ miR-122 ϩ 0.4511 ϫ miR-192 ϩ 0.6112 ϫ miR-21 Ϫ 0.1796 ϫ miR-223 Ϫ 0.2487 ϫ miR-26a Ϫ 0.3542 ϫ miR-27a ϩ 0.209 ϫ miR-801 was used to construct the ROC curve. The diagnostic performance for the established microRNA panel was evaluated by using ROC analysis. The AUC for the microRNA panel was 0.864 (95% CI, 0.826 to 0.895; sensitivity ϭ 68.6%, specificity ϭ 90.1%, Fig 2A) .
Validating the MicroRNA Panel
The parameters estimated from the training data set were used to predict the probability of being diagnosed with HCC for the independent validation data set (390 plasma samples). Similarly, the predicted Plasma MicroRNA Panel to Diagnose HCC www.jco.org probability was used to construct the ROC curve. The AUC of the microRNA panel was 0.888 (95% CI, 0.852 to 0.917; sensitivity ϭ 81.8%, specificity ϭ 83.5%, Fig 2B) .
The diagnostic performance of the microRNA panel in different Barcelona Clinic Liver Cancer (BCLC) stages was further evaluated ( Figs 2C-2F ). The corresponding AUCs for patients with BCLC stages 0, A, B, and C were 0.888, 0.888, 0.901, and 0.881, respectively. This indicated that the diagnostic performance of the microRNA panel was independent of disease status, which made it an optimal diagnostic tool.
The diagnostic accuracy of the microRNA panel was then evaluated according to AFP level. In the low AFP (Ͻ 400 ng/mL) group, the AUC of the microRNA panel was 0.879 (95% CI , 0.839 to 0.912; sensitivity ϭ 77.7%, specificity ϭ 84.5%; Data Supplement Fig 2A) . In the elevated AFP (Ն 400 ng/mL) group, the AUC of the microRNA panel was 0.910 (95% CI, 0.867 to 0.942; sensitivity ϭ 87.7%, specificity ϭ 83.5%; Data Supplement Fig 2B) .
The performance of the microRNA panel in differentiating the HCC group from the healthy, CHB, and cirrhosis groups was also evaluated, respectively (Fig 3) . The analysis demonstrated that the microRNA panel had high accuracy in discriminating HCC from healthy (AUC ϭ 0.941; 95% CI, 0.905 to 0.966; sensitivity ϭ 83.2%, specificity ϭ 93.9%), CHB (AUC ϭ 0.842; 95% CI, 0.792 to 0.883; sensitivity ϭ 79.1%, specificity ϭ 76.4%) and cirrhosis (AUC ϭ 0.884; 95% CI, 0.838 to 0.921; sensitivity ϭ 75.0%, specificity ϭ 91.1%).
DISCUSSION
Current methods for the diagnosis of HCC fall into two main categories: imaging and biomarker tests. However, the diagnostic performance of these modalities is unsatisfactory, particularly for the diagnosis of early-stage HCC. At this time, only 30% to 40% of patients with HCC are eligible for potentially curative intervention as a result of late clinical presentation and the lack of effective early B A detection measures. AFP has been used for many years as a serum marker for HCC diagnosis and screening.
22,23 However, it has been recognized that AFP has poor sensitivity in the detection of HCC and that AFP levels often increase in the absence of HCC (chronic hepatitis or cirrhosis) as well. 24, 25 Significant efforts to identify a better serum or plasma marker have met with limited success. The recent discovery of aberrant expression of microRNAs in HCC tissue paved the way for analyzing circulating microRNAs for the purpose of HCC diagnosis.
Our study revealed that plasma miR-122, miR-192, miR-21, miR-223, miR-26a, miR-27a, and miR-801 were potential circulating markers for diagnosing HCC. The microRNA panel with the seven microRNAs from the multivariate logistic regression model demonstrated high accuracy in the diagnosis of HCC, especially for patients with early BCLC stages (0 and A). The association at the tissue level between HCC and four of the seven microRNAs (miR-122, miR-21, miR-223, and miR-26a) in our study has been previously reported. MicroRNA-122 is the most abundant microRNA in the liver, and the repression of miR-122 in HCC has been reported by many investigators.
7,26-29 Coulouarn et al 29 showed that the repression of miR-122 correlated with HBV-related HCC, tumor size, and differentiation grade. Furthermore, miR-122 repression was associated with poor prognosis and an increase in metastatic properties. Ladeiro et al 8 demonstrated a significant overexpression of miR-21 in HCC as compared with that in benign tumor or nontumor liver tissue. Overexpression of miR-21 has been shown to participate in down-regulating the expression level of phosphatase and tensin homolog. 10 Wong et al 13 demonstrated significantly repressed miR-223 in both HCC tissue and 18 HCC cell lines and identified Stathmin1 as a putative target of miR-223 in HCC. Our previous study showed that patients whose HCC tumors had lower miR-26a expression experienced worse survival but better response to interferon therapy.
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Kota et al 31 found that the administration of miR-26a in a mouse model of HCC delivered by adeno-associated virus results in inhibition of cancer cell proliferation, induction of tumor-specific apoptosis, and dramatic protection from disease progression. The differential expression profile of miR122, miR-21, and miR-223, and their potential role in carcinoma pathway had been reported by other studies. Further functional study is needed to confirm the role of miR-192 and miR-801. Although miR-27a has been found to be an oncogene in gastric cancer, 32 our study is the first to our knowledge to report the importance of the miR-27a expression profile, along with miR-192 and miR-801, in association with HCC.
At the circulating blood level, the diagnostic performance of miR-21, miR-122, and miR-223 in discriminating patients with HCC from a healthy group was reported by Xu et al 17 . However, their study failed to distinguish HCC from chronic hepatitis. Qu et al 16 found miR-16 to have moderate diagnostic accuracy of HCC, with sensitivity of 72.1% and specificity of 88.8%. In our study, miR-16 did show significant down-regulation in HCC as compared with CHB (P Ͻ .01), but up-regulation as compared with cirrhosis. However, it did not meet our candidate microRNA selection criteria at the microarray level. Li et al 9 reported the extraordinarily high diagnostic accuracy of the serum microRNA profiles for the diagnosis of HCC (AUC ϭ 0.97-1.00) with microRNAs 10a, 125b, 223, 23a, 23b, 342-3p, 375, 423, 92a, and 99a. However, the need for different markers for different group comparisons with different critical values in their study (HCC v healthy, HCC v HBV, healthy v HBV, healthy v HCV, and HBV v HCV) raised concern about the robustness of the markers. Furthermore, these results have not been validated either internally or externally. Our study also confirmed that miR-23a, miR-23b, and miR-92a showed differential expression in the comparison of HCC versus CHB or HCC versus cirrhosis with the microarray platform. However, these microRNAs were not further studied at qRT-PCR level, because they failed to pass our selection criteria. Currently, there is no standard endogenous control for the circulating microRNA studies. The stable control (miR-1228) we used needs to be validated in more studies. Moreover, the patients' follow-up time in this study was only 1 to 3 years, limiting our current ability for prognostic analysis. In addition, our microRNA panel has yet to be validated across heterogeneous HCC patients, such as HCV-related HCC.
Compared with those studies of circulating microRNAs in diagnosing HCC, 9, 16, 17 our study is unique for the following reasons: First, we screened a large number of plasma microRNAs via microarrays, which enabled us to have better chance to identify potential diagnostic markers. Furthermore, we included not only HCC, healthy, and CHB groups but a cirrhosis group as well. It is well known that the pathogenesis of HCC is heterogenous and that multiple mechanisms of tumorigenesis could be involved (tumor suppressor gene, oncogene, viral effects, angiogenesis, etc). Nonetheless, we hypothesized that, similar to the adenoma-carcinoma sequence in colorectal cancer, the clinical pathway of most HBVrelated HCC may follow the four states: healthy, hepatitis, cirrhosis, and HCC. Because of the long incubation time, microRNA disturbance might happen during any of the states (hepatitis, cirrhosis, or HCC) before the clinical/pathophysiological manifestation of HCC. Thus, all the representative differential microRNAs from HCC versus healthy, HCC versus hepatitis, and HCC versus cirrhosis should be considered. Failure to do so might be the source of the unsatisfactory discrimination of HCC from hepatitis or cirrhosis in other studies. 9, 16, 17 In addition, the microRNA panel identified in our study was validated by using a large, independent cohort from two medical centers. In summary, we found a plasma microRNA panel in a large number of participants that differentiates HCC from healthy, CHB, and cirrhosis with a high degree of accuracy. Our study demonstrates that this plasma microRNA panel has considerable clinical value for the early diagnosis of HCC, so that more patients, who would have otherwise missed the curative treatment window, can benefit from the optimal therapy.
AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
The author(s) indicated no potential conflicts of interest. 
